<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666107</url>
  </required_header>
  <id_info>
    <org_study_id>#33245</org_study_id>
    <nct_id>NCT00666107</nct_id>
  </id_info>
  <brief_title>Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men</brief_title>
  <acronym>MIRB #862</acronym>
  <official_title>Pilot Study to Evaluate the Immunogenicity and Safety of the HPV Quadrivalent Vaccine (Gardasil) in HIV-infected Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy and safety of the quadrivalent vaccine (Gardasil)
      against the human papilloma virus (HPV) in HIV (human immunodeficiency virus) infected males.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective pilot study that will attempt to enroll approximately 150-200
      HIV-infected males followed regularly in the ID Primary Care Clinic at the VA Long Beach
      Healthcare System. All consenting patients will be given the HPV vaccine (Gardasil) in three
      intramuscular injections. Baseline antibody titers to HPV strains 16 and 18 will be obtained
      at day 0 and repeat levels will be obtained approximately 8 weeks after the completion of the
      vaccination series to determine whether patients without antibodies at baseline have now
      produced antibodies, or to determine the change in antibody levels in those patients who have
      evidence of antibodies prior to the first injection of the vaccine. Patients will undergo
      routine anal PAP smear with HPV DNA testing at baseline and another PAP smear/HPV test
      approximately 8 weeks after completion of the series. Patients will report any side effects
      of the vaccine to the PI. Patients will have blood work to monitor HIV-1 viral load and CD4
      lymphocytes counts at various points during the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Geometric Mean Titers of anti-HPV 16 and anti-HPV 18 antibodies</measure>
    <time_frame>nine months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine percentage of subjects who seroconverted or mounted a significant serologic response to each of the 2 antigens 16 and 18</measure>
    <time_frame>8-9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine how many patients, if any, develop evidence of anal HPV infection, as measured by development of a positive HPV test.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit</measure>
    <time_frame>nine months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Anal Cancer</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6</description>
    <other_name>HPV quadrivalent vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male veterans

          -  Age 18 or older

          -  HIV-positive

          -  Seen regularly in the ID Primary Care Clinic at the VA Long Beach Healthcare System

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Berman, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California Institute for Research and Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822-5201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002 Nov 1;35(9):1127-34. Epub 2002 Oct 14.</citation>
    <PMID>12384848</PMID>
  </reference>
  <reference>
    <citation>FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27.</citation>
    <PMID>17494925</PMID>
  </reference>
  <reference>
    <citation>Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF, MacMullen S, Esser MT, Paliard X. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol. 2002 Aug;76(15):7832-42.</citation>
    <PMID>12097595</PMID>
  </reference>
  <reference>
    <citation>Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005 May;6(5):271-8.</citation>
    <PMID>15863374</PMID>
  </reference>
  <reference>
    <citation>Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, HÃ¸ye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007 Jun 21;25(26):4931-9. Epub 2007 Apr 20.</citation>
    <PMID>17499406</PMID>
  </reference>
  <reference>
    <citation>Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5.</citation>
    <PMID>15577408</PMID>
  </reference>
  <reference>
    <citation>Bozzette SA, Phillips B, Asch S, Gifford AL, Lenert L, Menke T, Ortiz E, Owens D, Deyton L. Quality Enhancement Research Initiative for human immunodeficiency virus/acquired immunodeficiency syndrome: framework and plan. HIV-QUERI Executive Committee. Med Care. 2000 Jun;38(6 Suppl 1):I60-9. Review.</citation>
    <PMID>10843271</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>HIV</keyword>
  <keyword>Gardasil</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

